Publications by authors named "Daniel D Karp"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

4,409

Total Likes

100

Extended Reach

86,763

Social Features

20
V
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Eric A Klein, Ian M Thompson, Catherine M Tangen, John J Crowley, M Scott Lucia, Phyllis J Goodman, Lori M Minasian, Leslie G Ford, Howard L Parnes, J Michael Gaziano

October 2011

Videos about Article: user user

2 39 18 34 128

View All Article and Social Media Activity
P
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.
Blessie Elizabeth Nelson, Filip Janku, Siqing Fu, Ecaterina E Dumbrava, David S Hong, Daniel D Karp

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
Mirella Nardo, Mohamed A Gouda, Matthew J Reilley, Amadeo B Biter, Joann Lim, Daniel D Karp

J Immunother Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study.
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, Jing Gong, Selma Sulovic

Invest New Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
Jibran Ahmed, Bettzy Stephen, Muhammad R Khawaja, Yali Yang, Israa Salih, Daniel D Karp

Gynecol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers.
Jibran Ahmed, Filip Janku, Daniel D Karp, Sarina A Piha-Paul, Apostolia M Tsimberidou

Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, Hassan Ahmed Momin, Bulent Yilmaz, Daniel D Karp

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Learning From Mistakes: Navigating Medical Errors in Oncology From Prevention to Management.
Daniel D Karp, Jessica A Osburn, Mohamed A Gouda

J Immunother Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types.
Vijaykumar R Holla, Michael P Kahle, Sun-Hee Kim, Arash Ronaghy, Richard K Yang, Daniel D Karp

JCO Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies.
Joe Y Chang, Xinyan Xu, Girish S Shroff, Nathan I Comeaux, Wei Li, Daniel D Karp

J Immunother Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D Karp

NPJ Precis Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer.
Chad Tang, Genevieve P Hartley, Coline Couillault, Ying Yuan, Heather Lin, Daniel D Karp

BMJ Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Sarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp

Oncologist· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous submission of seven CTSA proposals: UM1, K12, R25, T32-predoctoral, T32-postdoctoral, and RC2: strategies, evaluation, and lessons learned.
Carolina Lema, Kwai Wa Cheng, Delanderia M Anderson, Charles C Miller, Daniel D Karp

J Clin Transl Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Blessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Daniel D Karp

Oncologist· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
Mehmet Altan, Janet Tu, Denái R Milton, Bulent Yilmaz, Yanyan Tian, Daniel D Karp

Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp

Cancer Chemother Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordance of HER2 Expression and/or Amplification on Repeat Testing.
Timothy P DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D Karp, Jaffer A Ajani

Mol Cancer Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Piha-Paul, Daniel D Karp

Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, Shiraj Sen, David S Hong, Daniel D Karp

Clin Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring Amplification.
Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A Previs, Anthony D Elias, Daniel D Karp

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period.
Hiba Dagher, Anne-Marie Chaftari, Ishwaria M Subbiah, Alexandre E Malek, Ying Jiang, Daniel D Karp

Elife· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.
Ji Son, Heather Y Lin, Siqing Fu, Amadeo B Biter, Ecaterina E Dumbrava, Daniel D Karp

J Immunother Precis Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Timothy A Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Daniel D Karp

Nat Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
Henry Hiep Vo, Siqing Fu, David S Hong, Daniel D Karp, Sarina Piha-Paul

NPJ Precis Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
Tito R Mendoza, David S Hong, Christine B Peterson, Bettzy Stephen, Ecaterina Dumbrava, Daniel D Karp

Sci Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis